By slowing down how quickly your stomach empties, it helps reduce your overall calorie intake, leading to sustainable weight loss when combined with lifestyle changes
For those meeting specific criteria, Wegovy (semaglutide) may be prescribed for obesity under NICE guidance (TA875), which requires a BMI of at least 35 kg/m (or 30 kg/m with weight-related comorbidities), specialist weight management service oversight, and time-limited use
Resources We Trust Mayo Clinic: Pros and Cons of GLP-1 Agonists for Weight Loss GLP-1 Weight-Loss Pills: What You Need to Know Yale Medicine: Johns Hopkins Medicine: The Pros, Cons, and Unknowns of Popular Weight Loss Drugs UCDavis Health: GLP-1 and Health: Beyond Weight Loss in the Ozempic Era Mount Sinai Today: What Are the Benefits of the New GLP-1 Weight Loss Pills
Its classification as a neuropeptide differentiates it from metabolic or receptor-targeted peptides, positioning DSIP within neuroregulatory research domains
Reaching maintenance dose faster to produce earlier weight loss results
